| Description |
Presently, the market for pharmaceuticals designed to treat pain is worth over $30 billion. The dynamics of the global pain market have been altered greatly over the past few years. The decline of the multi-billion dollar Cox-2 class has created a void in the marketplace, as well as difficulties for companies wishing to launch new drugs in the class. The Cox-2 crisis has consequently increased opportunities for alternative pain therapies.
Arrowhead’s Second Annual Pain Therapeutics Summit is being organized to provide an integral forum for a critical examination of and discussion of the trends and issues facing the field of pain therapeutics.
This conference will provide you with thoughful insight from key industry leaders concerning cutting edge drug discovery science and preclinical development trends as well as analysis of key clinical-stage pain therapies and newly marketed products.
Among other key issues to be discussed include:
* the increasing importance of diagnostics in the field of pain management
* status of abuse-resistant opioids in development
* the utilization of new drug delivery technologies in the development of new and re-branded pain therapeutics
Key Takeaways
* Learn about the latest developments and the most recent commercial breakthroughs in the area of pain therapeutics
* Learn what innovative new therapies are driving investment and clinical development in the area of pain therapeutics
* Gain a better sense of the impact the biotech industry is having on the development of pain therapeutics
* Network with leaders from the pharma, biotech, specialty pharma and drug delivery industries
For more infomation about this conference, please contact us. To enquire about sponsorship and/or exhibiting at this conference please e-mail marketing@arrowheadpublishers.com.
Key Themes
* Clinical development case studies and analysis in pain therapeutics
* New drug discovery and novel targets in the area of pain management
* An examination of regulatory issues facing developers of new pain therapies
* Big pharma’s involvement in the pain field: consolidation or fragmentation?
* A review and analysis of key developmental stage therapies for neuropathic pain, migraine, back pain, fibromyalgia, cancer pain, arthritic pain, and other type of pain
* Analysis and case studies of successful commercialization strategies for pain therapies
* A review of current development status for novel targets such as AMPA/kainate, ion channels, delta opioids, CGRP and NK-1
* Specialty Pharma’s drug development activities in the area of pain management
* Developments in the race to market abuse-resistant opioids
* Drug delivery technologies and their application to the field of pain management
Who Should Attend
VPs, Managers, Heads, Directors and Associates from the areas of:
* Pain research
* Neuroscience drug discovery
* Pain management
* Clinical development / research
* Business development / licensing
* Alliance management
* Drug delivery
* Pain management devices
as well as individuals from
* Investment banks and venture capitalist firms
* Academic institutions
* Consultancies
|
|
